Revelation Biosciences Amends S-1 for Continuous Securities Offering
Ticker: REVBW · Form: S-1/A · Filed: May 23, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | S-1/A |
| Filed Date | May 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, Biotechnology, Pharmaceuticals, SEC Filing, Continuous Offering, Capital Raise, Regulatory Compliance
Related Tickers: REVBW
TL;DR
**REVBW is gearing up for continuous capital raises, signaling a long-term funding strategy that could lead to dilution but also fuel critical drug development.**
AI Summary
REVELATION BIOSCIENCES, INC. (REVBW) filed an S-1/A on May 23, 2025, as an amendment to its initial S-1 registration statement, indicating a continuous offering of securities under Rule 415. The company, a pharmaceutical preparations firm (SIC 2834), is headquartered in San Diego, CA, and operates with a fiscal year ending December 31. This filing updates the registration for the proposed sale to the public, which is expected to commence as soon as practicable after the effective date. The company's business address is 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122, with a business phone of 650-800-3717. James Rolke serves as the Chief Executive Officer. The filing also notes the company's former name, Petra Acquisition Inc., which changed on April 23, 2020. No specific revenue or net income figures were provided in the excerpt, but the amendment focuses on the procedural aspects of the securities offering. The primary business change highlighted is the continuous offering mechanism, suggesting a strategic outlook for ongoing capital raises. Key risks, while not detailed in this excerpt, would typically revolve around clinical trial outcomes, regulatory approvals, and market acceptance for a pharmaceutical company.
Why It Matters
This S-1/A filing signals REVELATION BIOSCIENCES' intent to maintain flexibility in raising capital through a continuous offering, which is crucial for a pre-revenue biotech firm. For investors, it means potential dilution but also ongoing funding for drug development, impacting future stock performance. Employees and customers will see this as a commitment to long-term operations and product development. In the competitive pharmaceutical landscape, consistent access to capital is vital for advancing clinical trials and bringing new therapies to market, positioning REVBW to potentially compete with larger players in specific therapeutic areas.
Risk Assessment
Risk Level: medium — The risk level is medium because, as a pharmaceutical preparations company (SIC 2834), REVELATION BIOSCIENCES faces inherent high risks associated with drug development, clinical trials, and regulatory approvals. However, the S-1/A filing itself is a procedural amendment for a continuous offering, which, while indicating potential future dilution, doesn't introduce immediate new operational risks. The continuous offering mechanism under Rule 415 provides flexibility but also suggests an ongoing need for capital, which is typical for early-stage biotechs.
Analyst Insight
Investors should monitor REVELATION BIOSCIENCES' future filings for details on the specific terms and uses of proceeds from this continuous offering. Evaluate the company's pipeline progress and clinical trial results, as these will be the primary drivers of value for a pharmaceutical company. Consider the potential for dilution as new securities are offered.
Key Numbers
- 333-287423 — Registration No. (SEC registration number for the S-1/A filing)
- 2025-05-23 — Filing Date (Date the S-1/A was filed with the SEC)
- 2834 — SIC Code (Primary Standard Industrial Classification for Pharmaceutical Preparations)
- 84-3898466 — IRS Employer Identification Number (Revelation Biosciences' EIN)
- 2020-04-23 — Date of Name Change (Date Petra Acquisition Inc. changed to Revelation Biosciences, Inc.)
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant in S-1/A filing
- James Rolke (person) — Chief Executive Officer of Revelation Biosciences, Inc.
- U.S. Securities and Exchange Commission (regulator) — Governing body for S-1/A filing
- J.P. Galda, Esq. (person) — Counsel for Communications
- J.P. Galda & Co. (company) — Law firm for Communications
- Charles Phillips, Esq. (person) — Counsel for Communications
- Ellenoff Grossman & Schole LLP (company) — Law firm for Communications
- Petra Acquisition Inc. (company) — Former name of Revelation Biosciences, Inc.
- San Diego, CA (location) — Principal executive offices of Revelation Biosciences, Inc.
- 650-800-3717 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of Revelation Biosciences' S-1/A filing?
The S-1/A filing by Revelation Biosciences is an amendment to its initial S-1 registration statement, primarily to register securities for a proposed delayed or continuous offering pursuant to Rule 415 under the Securities Act of 1933. This allows the company flexibility in raising capital over time.
When was Revelation Biosciences' S-1/A filed with the SEC?
Revelation Biosciences' S-1/A was filed with the U.S. Securities and Exchange Commission on May 23, 2025, under accession number 0001213900-25-047104.
Who is the CEO of Revelation Biosciences, Inc.?
James Rolke is the Chief Executive Officer of Revelation Biosciences, Inc. His contact information is listed as 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122, with a phone number of 650-800-3717.
What is Revelation Biosciences' primary industry classification?
Revelation Biosciences, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which corresponds to 'Pharmaceutical Preparations.' This indicates their primary business is in the pharmaceutical sector.
What was Revelation Biosciences' former company name?
Revelation Biosciences, Inc. was formerly known as Petra Acquisition Inc. The name change occurred on April 23, 2020, as noted in the S-1/A filing.
Where are Revelation Biosciences' principal executive offices located?
Revelation Biosciences' principal executive offices are located at 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122. Their business phone number is 650-800-3717.
What does a continuous offering under Rule 415 mean for investors in REVBW?
For investors, a continuous offering under Rule 415 means that REVBW can sell securities periodically over an extended period without filing a new registration statement for each sale. This provides the company with funding flexibility but could lead to potential share dilution if new shares are issued, impacting existing shareholders.
What are the potential risks associated with Revelation Biosciences' business?
As a pharmaceutical preparations company, Revelation Biosciences faces significant risks including the high costs and uncertainties of drug development, the potential for clinical trial failures, the need for regulatory approvals from bodies like the FDA, and market acceptance of any developed products. These inherent risks are typical for companies in SIC 2834.
Who are the legal counsels mentioned in Revelation Biosciences' S-1/A filing?
The legal counsels mentioned for communications in Revelation Biosciences' S-1/A filing are J.P. Galda, Esq. of J.P. Galda & Co., and Charles Phillips, Esq. of Ellenoff Grossman & Schole LLP.
When is the proposed sale to the public expected to commence for Revelation Biosciences?
The proposed sale to the public for Revelation Biosciences is expected to commence as soon as practicable after the effective date of this Registration Statement, as indicated in the S-1/A filing.
Industry Context
Revelation Biosciences operates within the Pharmaceutical Preparations industry (SIC 2834). This sector is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on continuous capital infusions to fund clinical trials and navigate the path to market approval.
Regulatory Implications
As a pharmaceutical company, Revelation Biosciences is subject to stringent regulations from bodies like the FDA. The S-1/A filing itself is a regulatory requirement for public offerings. Key risks would include the success of clinical trials, obtaining regulatory approvals, and compliance with ongoing reporting obligations.
What Investors Should Do
- Review the full S-1/A filing for detailed risk factors and business strategy.
- Monitor future filings for updates on the continuous offering and company progress.
Key Dates
- 2025-05-23: Filing of S-1/A Amendment — Indicates the company is actively pursuing a public offering of securities on a continuous basis, signaling a need for ongoing capital.
- 2020-04-23: Name Change from Petra Acquisition Inc. — Marks a significant rebranding or strategic shift for the company, moving from a previous identity to Revelation Biosciences, Inc.
Glossary
- S-1/A
- An amendment to an initial S-1 registration statement filed with the SEC, used to update or correct information before a securities offering becomes effective. (This filing indicates Revelation Biosciences is amending its registration to offer securities.)
- Rule 415
- A regulation that permits companies to register securities for a continuous offering or sale over a period of time, rather than in a single transaction. (Revelation Biosciences is utilizing Rule 415 for a continuous offering, suggesting a strategy for ongoing capital raising.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations, indicating the company's primary business activity. (Classifies Revelation Biosciences within the pharmaceutical industry, highlighting its core business focus.)
- Fiscal Year End 1231
- Indicates that the company's financial reporting year concludes on December 31st. (Essential for understanding the timing of financial statements and reporting cycles.)
Year-Over-Year Comparison
This S-1/A filing is an amendment to an initial registration statement, not a comparison to a prior year's financial filing. The primary change highlighted is the adoption of a continuous offering mechanism under Rule 415, indicating a strategic shift towards ongoing capital formation rather than a single, discrete offering.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on May 23, 2025 by James Rolke regarding REVELATION BIOSCIENCES, INC. (REVBW).